IT1246777B
(it)
*
|
1991-04-12 |
1994-11-26 |
Boehringer Mannheim Italia |
Aminoacil derivati di acidi gem-difosfonici,un processo per la loro preparazione e composizioni farmaceutiche che li contengono
|
IT1246778B
(it)
*
|
1991-04-12 |
1994-11-26 |
Boehringer Mannheim Italia |
Nitrosocarbamoil derivati di acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono
|
US5270365A
(en)
*
|
1991-12-17 |
1993-12-14 |
Merck & Co., Inc. |
Prevention and treatment of periodontal disease with alendronate
|
US6399592B1
(en)
|
1992-12-23 |
2002-06-04 |
Merck & Co., Inc. |
Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
|
US5510517A
(en)
*
|
1993-08-25 |
1996-04-23 |
Merck & Co., Inc. |
Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
|
TW257765B
(fi)
*
|
1993-08-25 |
1995-09-21 |
Merck & Co Inc |
|
US5462932A
(en)
*
|
1994-05-17 |
1995-10-31 |
Merck & Co., Inc. |
Oral liquid alendronate formulations
|
US5449819A
(en)
*
|
1994-06-06 |
1995-09-12 |
Merck & Co., Inc. |
Process for removing waste pox, alendronate and its by products
|
US5589691A
(en)
*
|
1994-06-06 |
1996-12-31 |
Merck & Co., Inc. |
Process for recovery and recycle of methanesulfonic acid and phosphorous acid
|
US5780455A
(en)
*
|
1994-08-24 |
1998-07-14 |
Merck & Co., Inc. |
Intravenous alendronate formulations
|
JPH10504839A
(ja)
*
|
1995-02-17 |
1998-05-12 |
メルク エンド カンパニー インコーポレーテッド |
非脊椎骨折のリスクを減少させる方法
|
TW393488B
(en)
*
|
1995-04-20 |
2000-06-11 |
Merck & Co Inc |
Process for making 1-hydrox-ybisphosphonates
|
CA2219354A1
(en)
*
|
1995-05-12 |
1996-11-14 |
Merck & Co., Inc. |
Prevention of tooth loss by the administration of alendronate or its salts
|
JP3344726B2
(ja)
*
|
1995-06-06 |
2002-11-18 |
メルク エンド カンパニー インコーポレーテッド |
無水アレンドロネート一ナトリウム塩製剤
|
AU5973496A
(en)
|
1995-06-06 |
1996-12-24 |
Merck & Co., Inc. |
Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
|
KR100192215B1
(ko)
*
|
1996-09-03 |
1999-06-15 |
강재헌 |
3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
|
PL332496A1
(en)
*
|
1996-10-04 |
1999-09-13 |
Merck & Co Inc |
Liquid alendronate preparations
|
CA2197267C
(en)
*
|
1997-02-11 |
2000-02-08 |
Yong Tao |
Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
|
IL138404A
(en)
|
1998-04-29 |
2004-07-25 |
Procter & Gamble |
Process for the preparation of 1 - [[[5- (4-chlorophenyl) -2-furanyl] methylene] amino] - 3- (4-methyl-1-piperazinyl) butyl] -2,4 imidazolidinedione dihydrochloride
|
EP1075474B1
(en)
|
1998-04-29 |
2004-09-08 |
The Procter & Gamble Company |
Process for making 1,3-disubstituted-4-oxocyclic ureas
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
EP1088333A4
(en)
|
1998-06-24 |
2005-08-10 |
Merck & Co Inc |
METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
|
US6008207A
(en)
*
|
1998-08-13 |
1999-12-28 |
Merck & Co., Inc. |
Anhydrous alendronate monosodium salt formulations
|
NZ510682A
(en)
|
1998-08-27 |
2003-09-26 |
Teva Pharma |
Hydrate forms of alendronate sodium useful for combating bone resorption
|
EP1702924A3
(en)
*
|
1998-08-27 |
2007-07-18 |
Teva Pharmaceutical Industries Ltd |
Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
US6331533B1
(en)
|
1998-11-16 |
2001-12-18 |
Merck & Co., Inc. |
Method for inhibiting dental resorptive lesions
|
KR100327786B1
(ko)
*
|
1999-03-25 |
2002-03-14 |
유승필 |
4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산 또는 이의 염의 제조방법
|
US6315566B1
(en)
|
1999-05-18 |
2001-11-13 |
3M Innovative Properties Company |
Dental materials
|
US6143919A
(en)
*
|
1999-05-18 |
2000-11-07 |
3M Innovative Properties Company |
Polymerizable acidic compounds and methods of preparation
|
US6963008B2
(en)
*
|
1999-07-19 |
2005-11-08 |
Teva Pharmaceutical Industries Ltd. |
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
ES2153794B1
(es)
|
1999-08-06 |
2001-10-16 |
Medichem Sa |
Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
|
US6677320B2
(en)
|
2000-01-20 |
2004-01-13 |
Hoffmann-La Roches Inc. |
Parenteral bisphosphonate composition with improved local tolerance
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
KR100327787B1
(ko)
*
|
2001-02-27 |
2002-03-15 |
유승필 |
4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산 일나트륨 삼수화물의 제조방법
|
US6558702B2
(en)
|
2001-04-13 |
2003-05-06 |
Alkermes Controlled Therapeutics, Inc. |
Method of modifying the release profile of sustained release compositions
|
US20060269602A1
(en)
*
|
2001-04-13 |
2006-11-30 |
Dasch James R |
Method of modifying the release profile of sustained release compositions
|
TR200101250A2
(tr)
*
|
2001-05-10 |
2003-04-21 |
E�S Eczaciba�I �Zg�N K�Myasal �R�Nler Sanay� A.�. |
4-amino-1-hidroksibutiliden-1,1-bifosfonik asit veya tuzlarının hazırlanmasına ilişkin proses
|
GB0115824D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Rhodia Cons Spec Ltd |
Improved solvent systems
|
AU2002360619B2
(en)
*
|
2001-12-21 |
2006-10-05 |
Allergan Pharmaceuticals International Limited |
Method for the treatment of bone disorders
|
JP4502641B2
(ja)
*
|
2002-01-24 |
2010-07-14 |
ティルタン ファーマ リミテッド |
抗癌組み合わせおよびその使用方法
|
ITMI20020908A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione di sodio alendronato
|
KR20140021045A
(ko)
*
|
2002-05-10 |
2014-02-19 |
에프. 호프만-라 로슈 아게 |
골다공증 치료 및 예방용 비스포스폰산
|
US7038083B2
(en)
*
|
2002-05-17 |
2006-05-02 |
Teva Pharmaceutical Industries, Ltd. |
Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons
|
JP2005534653A
(ja)
*
|
2002-06-06 |
2005-11-17 |
メルク フロスト カナダ アンド カンパニー |
眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体
|
JP4485117B2
(ja)
*
|
2002-06-27 |
2010-06-16 |
日東電工株式会社 |
保護剥離用フィルム
|
US7109223B2
(en)
*
|
2002-08-28 |
2006-09-19 |
Merck & Co. Inc. |
Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
SG174628A1
(en)
*
|
2002-12-20 |
2011-10-28 |
Hoffmann La Roche |
High dose ibandronate formulation
|
US20040206932A1
(en)
*
|
2002-12-30 |
2004-10-21 |
Abuelyaman Ahmed S. |
Compositions including polymerizable bisphosphonic acids and methods
|
HUP0300227A2
(hu)
*
|
2003-01-28 |
2004-09-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
|
US7449499B2
(en)
*
|
2003-08-12 |
2008-11-11 |
3M Innovative Properties Company |
Self-etching dental compositions and methods
|
CA2535359A1
(en)
|
2003-08-21 |
2005-03-03 |
Merck Frosst Canada Ltd. |
Cathepsin cysteine protease inhibitors
|
PL1656386T3
(pl)
|
2003-08-21 |
2010-05-31 |
Sun Pharmaceuticals Ind Ltd |
Proces wytwarzania związków kwasu difosfonowego
|
CN1852719A
(zh)
*
|
2003-09-19 |
2006-10-25 |
辉瑞产品公司 |
包括2-亚烷基-19-去甲-维生素d衍生物和二膦酸盐的组合的药物组合物和方法
|
WO2005035542A1
(en)
*
|
2003-10-14 |
2005-04-21 |
Pliva-Istrazivanje I Razvoj D.O.O. |
Solid-state form of alendronate sodium and preparation thereof
|
US20050181043A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Indranil Nandi |
Alendronate salt tablet compositions
|
SMAP200600038A
(it)
|
2004-05-24 |
2006-12-27 |
Procter & Gamble |
Forme di dosaggio di bisfosfonati
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
JP5214242B2
(ja)
*
|
2004-07-08 |
2013-06-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
歯科用の方法、組成物、および酸感受性色素を含むキット
|
KR101260525B1
(ko)
*
|
2004-08-11 |
2013-05-06 |
쓰리엠 도이칠란드 게엠베하 |
다수의 산성 화합물을 포함하는 자체-접착성 조성물
|
US7361761B2
(en)
*
|
2004-09-28 |
2008-04-22 |
Orchid Chemicals & Pharmaceuticals Ltd. |
Process for the preparation of bisphosphonic acid
|
ES2510494T3
(es)
|
2005-03-02 |
2014-10-21 |
Merck Sharp & Dohme Corp. |
Composición para la inhibición de la catepsina K
|
EP1865928A1
(en)
*
|
2005-03-17 |
2007-12-19 |
Elan Pharma International Limited |
Nanoparticulate biphosphonate compositions
|
WO2006134603A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Jubilant Organosys Limited |
Process for producing bisphosphonic acids and forms thereof
|
AR054673A1
(es)
|
2005-07-28 |
2007-07-11 |
Gador Sa |
Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
|
US8003820B2
(en)
*
|
2005-10-20 |
2011-08-23 |
Dr. Reddy's Laboratories Limited |
Process for preparing bisphosphonic acids
|
EP1803727B1
(en)
|
2005-12-27 |
2009-03-11 |
IPCA Laboratories Limited |
Improved process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts
|
WO2007083240A2
(en)
|
2006-01-20 |
2007-07-26 |
Aurobindo Pharma Limited |
An improved process for the preparation of bisphosphonic acids
|
EP1987046A1
(en)
*
|
2006-02-20 |
2008-11-05 |
Alembic Limited |
An improved process for the preparation of biphosphonic derivatives
|
US8076483B2
(en)
*
|
2006-05-11 |
2011-12-13 |
M/S. Ind Swift Laboratories Limited |
Process for the preparation of pure risedronic acid or salts
|
CA2570949A1
(en)
*
|
2006-12-12 |
2008-06-12 |
Apotex Pharmachem Inc. |
Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
|
JP5507256B2
(ja)
*
|
2006-12-13 |
2014-05-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
酸性成分及び光退色性染料を有する歯科用組成物の使用方法
|
US20090170815A1
(en)
*
|
2007-12-28 |
2009-07-02 |
Roxane Laboratories Incorporated. |
Alendronate oral liquid formulations
|
WO2010003704A2
(en)
*
|
2008-07-11 |
2010-01-14 |
Synthon B.V. |
Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
|
US20100130746A1
(en)
*
|
2008-11-26 |
2010-05-27 |
Martin Kas |
Process for Making Zoledronic Acid
|
WO2010143193A1
(en)
|
2009-06-11 |
2010-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
WO2011023280A1
(en)
|
2009-08-28 |
2011-03-03 |
Synthon B.V. |
Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
|
BR112012007554B1
(pt)
|
2009-10-02 |
2018-09-04 |
Monsanto Technology Llc |
método para a fabricação de ácidos amino hidróxi disfofônico
|
CA2738045C
(en)
|
2010-05-28 |
2019-02-19 |
Simon Fraser University |
Conjugate compounds, methods of making same, and uses thereof
|
CA2820019A1
(en)
|
2010-12-06 |
2012-06-14 |
Effrx Pharmaceuticals Sa |
Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
|
EP2675440B1
(en)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2013008240A2
(en)
|
2011-07-13 |
2013-01-17 |
Yissum Research Development Company Of The Hebrew University Ofjerusalem Ltd. |
Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
US9458181B2
(en)
|
2013-10-08 |
2016-10-04 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
US9650414B1
(en)
|
2014-05-30 |
2017-05-16 |
Simon Fraser University |
Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
|
CN107849072B
(zh)
|
2015-06-12 |
2020-12-15 |
西蒙弗雷泽大学 |
酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
|
EP3827010A4
(en)
|
2018-07-23 |
2022-03-16 |
Brise Pharmaceuticals Co., Ltd. |
BISPHOSPHONATE-DRUG CONJUGATES
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|